DESIGN OF HEPATITIS E VIRUS GENOTYPE 1 RECOMBINANT CAPSID PROTEIN: CLONING, EXPRESSION, PURIFICATION, EVALUATION OF THE ANTIGENIC PROPERTIES

Cover Page


Cite item

Full Text

Abstract

Aim. The development of the hepatitis E virus (HEV) genotype 1 recombinant capsid protein. Materials and methods. Escherichia coli strains, plasmid vectors, serological and clinical samples, ELISA reagent kits, molecular biological, bioinformatic, biotechnological, biochemical and serological methods. Results. Using HEV genotype 1 DNA copy of subgenomic virus RNA we made E.coli strains producing recombinabt capsid protein, containing C-terminal fragment of ORF2 protein fused to E.coli beta-galactosidase. Recombinant protein ORF2 had been isolated from the inclusion bodies of the E.coli biomass and purified by size exclusion chromatography. By Western blotting it had been shown specific interaction of the recombinant polypeptide with anti-HEV IgG from pool of positive sera. Antigenic specificity of the recombinant polypeptide had been confirmed by enzyme-linked immunosorbent assay with sera of hepatitis E patients and reference groups: healthy donors, patients with hepatitis А, В, C, infectious mononucleosis and cytomegalovirus infection, HIV-infected patients. Conclusion. HEV genotype 1 ORF2 recombinant antigen had been developed, and its possible use in diagnostic tests had been experimentally shown.

About the authors

G. I. Alatortseva

Mechnikov Research Institute of Vaccines and Sera

Author for correspondence.
Email: noemail@neicon.ru
Russian Federation

A. V. Sidorov

Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

L. N. Nesterenko

Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

L. N. Luhverchik

Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

V. V. Dotsenko

Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

I. I. Amiantova

Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

V. Yu. Kabargina

Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

A. V. Milovanova

Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

D. S. Vorobev

Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

Yu. I. Ammur

Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

V. M. Blinov

Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

A. Z. Nurmatov

Scientific Production Association «Preventive Medicine»

Email: noemail@neicon.ru
Russian Federation

Z. Sh. Nurmatov

Scientific Production Association «Preventive Medicine»

Email: noemail@neicon.ru
Russian Federation

D. A. Baiyzbekova

Scientific Production Association «Preventive Medicine»

Email: noemail@neicon.ru
Russian Federation

O. T. Kasymov

Scientific Production Association «Preventive Medicine»

Email: noemail@neicon.ru
Russian Federation

K. K. Kyuregyan

Mechnikov Research Institute of Vaccines and Sera, Russian Medical Academy of Continuous Professional Education

Email: noemail@neicon.ru
Russian Federation

M. I. Mikhailov

Mechnikov Research Institute of Vaccines and Sera, Russian Medical Academy of Continuous Professional Education

Email: noemail@neicon.ru
Russian Federation

S. V. Zhavoronok

Belarusian State Medical University

Email: noemail@neicon.ru
Russian Federation

V. V. Zverev

Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

References

  1. Алаторцев В.Е., Алаторцева Г.И. Патент РФ, 1992, № 2071501 на изобретение «Вектор pEL5a, предназначенный для экспрессии чужеродной ДНК».
  2. Алаторцев В.Е., Алаторцева Г.И. Патент РФ, 1992, № 2043409 на изобретение «Штамм бактерий Escherichia coli, используемый для получения рекомбинантных белков».
  3. Алаторцева Г.И., Гринев А.А., Амиантова И.И. и др. Получение рекомбинантных полипептидов, содержащих антигенные детерминанты вируса гепатита Е. Вопросы вирусологии. 1998, 43 (6): 266-269.
  4. Алаторцева Г.И., Сидоров А.В., Нестеренко Л.Н. и др. Получение рекомбинантного аналога гликопротеина е вируса Varicella zoster: клонирование, экспрессия и исследование антигенных свойств. Эпидемиология и вакцинопрофилактика. 2016, 15, 1 (86): 77-85.
  5. Гловер Д. Новое в клонировании ДНК. Методы. М., 1989.
  6. Практическая химия белка. М., 1989.
  7. Маниатис Т., Фрич Э., Сэмбрук Дж. Методы генетической инженерии. Молекулярное клонирование. М., Мир, 1984.
  8. Hyams С., Mabayoje D.A., Copping R. et al. Serological cross reactivity to CMV and EBV causes problems in the diagnosis of acute hepatitis E virus infection. J. Med. Virol, 2014, 86 (3): 478-483.
  9. Koonin E.V., Gorbalenya A.E., Purdy M.A. et al. Computer-assisted assignment of functional domains in the nonstructural polyprotein of hepatitis E virus: delineation of an additional group of positive-strand RNA plant and animal viruses. Proc. Natl. Acad. Sci. USA. 1992, 89 (17): 8259-8263.
  10. Kumar S., Tamura K., Nei M. MEGA 3: Integrated software for molecular evolutionary genetics analysis and sequence alignment. Briefings in Bioinformatics. 2004, 5: 150-163.
  11. Kyte J., Doolittle R.F. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 1983, 157 (1): 105-132.
  12. Li S.W., Zhang J., He Z.Q. et al. Mutational analysis of essential interactions involved in the assembly of hepatitis E virus capsid. J. Biol. Chem. 2005, 280 (5): 3400-3406.
  13. Osterman A. et al. Systematic screening for novel, serologically reactive Hepatitis E Virus epitopes. Virology J. 2012, 9: 28-32.
  14. Resenchuk S.М., Blinov V.M. Alignment service: creation and processing of alignments of sequences of unlimited length. Comput. Appl. Biosci. (CABIOS). 1995, 11 (1): 7-11.
  15. Towbin H., Staehlin Т., Gordon Y. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA. 1979, 76 (9): 4350-4359.
  16. Ulanova T.I., Obriadina A.P., Talekar G. et al. A new artificial antigen of the hepatitis E virus. J. Immunoassay Immunochem. 2009, 30 (1): 18-39.
  17. Xinjie Wang, Qin Zhao, Lu Dang et al. Characterization of two novel linear В-cell epitopes in the capsid protein of avian hepatitis E virus (HEV) that are common to avian, swine, and human HEVs. J. Virol. 2015, 4, 89 (10): 5491-501.
  18. Yamashita Т., Mori Y, Miyazaki N. et al. Matsuura biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure. Proc. Natl. Acad. Sci. USA. 2009, 106 (31): 12986-12991.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2017 Alatortseva G.I., Sidorov A.V., Nesterenko L.N., Luhverchik L.N., Dotsenko V.V., Amiantova I.I., Kabargina V.Y., Milovanova A.V., Vorobev D.S., Ammur Y.I., Blinov V.M., Nurmatov A.Z., Nurmatov Z.S., Baiyzbekova D.A., Kasymov O.T., Kyuregyan K.K., Mikhailov M.I., Zhavoronok S.V., Zverev V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies